Latest filing published 19 Dec 2025 for Avidity Biosciences, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
John B. Moriarty discloses dealings in 4 companies, chiefly Alexion Pharmaceuticals Inc, Avidity Biosciences, Inc. and Portola Pharmaceuticals Inc. In total, 72 filings cover trades dated from 10 December 2012 to 27 February 2026.
The open-market record consists of 40 sales worth €8.5M, with no purchase. Besides market trades, the filings include 22 share grants and 6 option exercises. 2026 to date brings no purchases and 1 sale.
The record was last updated on 27 February 2026 with a transaction in Avidity Biosciences, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations